Financial Performance - Total revenue for Q3 2025 was $78 million, a 43% decrease year-over-year[35] - Adjusted EBITDA for Q3 2025 was $13 million, compared to $22 million in Q3 2024[37] - Free cash flow for Q3 2025 was -$1 million, impacted by $55 million in severance payments and a $75 million settlement payment[39] - Capital Expenditures (CapEx) in Q3 2025 were $6 million, down 63% year-over-year[39] - The company ended the quarter with $112 million in cash and investments, resulting in a net cash balance of $49 million[42] Business Strategy and Outlook - The company is splitting into two units: Chegg Skilling (growth business) and legacy academic services (cash flow generation)[8] - Chegg Skilling is expected to have sustainable double-digit growth[8] - Chegg Skilling revenue is expected to increase approximately 14% year-over-year in Q4 2025, driving total revenue of approximately $70 million for the year[10] - Q4 2025 total net revenue is guided to be between $70 million and $72 million[44] - Q4 2025 Adjusted EBITDA is guided to be between $10 million and $11 million[44] - Full-year 2025 CapEx is anticipated to be approximately $27 million, with a targeted further reduction of approximately 60% in 2026[39]

Acquisition of Ask Sage - BigBear.ai announced the acquisition of Ask Sage, an advanced generative-AI platform tailored for government agencies and highly regulated industries[11, 13] - Ask Sage's ARR grew 6X from '24-'25 and currently serves 16,000 government teams[13] - Ask Sage offers a secure platform for AI use in USG/DoD, reliable data and system connectivity, a marketplace for AI-powered tools, and services for custom AI apps[26] - Synergies between Ask Sage and BigBear.ai include cross-selling, customer expansion, tech integration, and go-to-market strategies[28] Financial Highlights (Q3 2025) - The company reported a record ending cash and investments balance of $715 million[33, 34] - The company had a net positive cash and investments position of almost $575 million as of the end of Q3[34] - For the three months ended September 30, 2025, net loss was $2521 thousand, compared to a net loss of $15135 thousand for the three months ended September 30, 2024[40] - For the three months ended September 30, 2025, Adjusted EBITDA was $(9401) thousand[40] - Revenues for the three months ended September 30, 2025 were $33143 thousand with a gross margin of 22.4% and an adjusted gross margin of 27.7%[43] Strategic Focus - The company focuses on disruptive AI software for national security, smart & secure travel & trade, and dual-use platform-level AI[18, 19]

Moving Infrastructure Forward Q3 2025 Update Presentation November 10, 2025 Geom Slide Title – 28 Franklin Gothic Med Header – 14 Franklin Gothic Book Content Text – 14 – 40 – 64 20 – 135 – 211 129 – 200 Franklin Gothic Book Chart Content – 10 RGB 33 – 255 205 – 217 – 225 74 – 88 – 135 Outline: black, ½ pt. 255 – 177 – 0 33 – 40 – 64 1 SAFE HARBOR STATEMENT This presentation is for informational purposes only and contains forward-looking statements within the meaning of the "safe harbor" provisions of the P ...

Financial Performance - Total operating expenses for Q3 2025 were $23018 thousand, compared to $9740 thousand in Q3 2024[16] - R&D expenses for Q3 2025 were $10307 thousand[16] - G&A expenses for Q3 2025 were $12711 thousand[16] - Net loss for Q3 2025 was $21690 thousand, compared to a net loss of $8679 thousand in Q3 2024[16] - The company's cash, liquidity fund, time deposits, and U S treasury bills totaled $2756 million[16] - Total operating cash outflow for the third quarter was approximately $93 million, compared to $86 million in the second quarter[16] Pipeline and Regulatory Updates - The company completed a $15 million registered direct offering and a $125 million private placement, with potential for an additional $165 million upon full warrant exercise[13] - The pivotal phase 3 DRAGON trial in Stargardt disease (STGD) has been completed, with topline data expected in Q4 2025[13] - China's NMPA has agreed to accept a New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease based on interim analysis results of the DRAGON trial[13] - The United Kingdom's MHRA has agreed to accept a Conditional Marketing Authorization application for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results of the DRAGON trial[13]

In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, Free Cash Flow, non-GAAP net dollar-based retention, non-GAAP net income, non-GAAP net income margin, non-GAAP diluted EPS, and litigation related expenses. We believe that this information can assist investors in evaluating our operational trends, financial performance, and ...

INO-3107 Program & Regulatory Updates - INOVIO completed the rolling BLA submission for INO-3107, seeking accelerated approval, with file acceptance expected by the end of the year[11] - If Priority Review is granted, a potential PDUFA date in mid-2026 is anticipated[11, 44] - The company has requested a Type D meeting with the FDA to discuss options for the confirmatory trial design[13] - In a Phase 1/2 trial, 72% of patients saw a 50-100% reduction in surgeries in Year 1[14] - A retrospective trial (RRP-002) showed clinical outcomes maintained or improved upon through year 2 and into year 3 with no additional dosing[14] - Mean surgeries per year decreased by 78% from pre-treatment Year -1 (4.1 surgeries) to Year 2 (0.9 surgeries)[16] Commercialization & Financials - Market research supports a preferred product profile for INO-3107, with 72% overall response rate (50% to 100% reduction in surgeries) in year 1 and 86% in year 2[27] - Operating expenses decreased by 22% to $212 million for the three months ended September 30, 2025, compared to $273 million in 2024[33] - Net loss for the three months ended September 30, 2025, was $455 million, which includes a non-cash loss on fair value adjustment of common stock warrant liabilities of $225 million[33] - Cash, cash equivalents, and short-term investments totaled $508 million as of September 30, 2025, providing a cash runway projected into 2Q 2026[34]

Third Quarter 2025 Earnings Conference Call Copyright © 2025 Peraso Inc. Disclaimer This presentation is for information purposes only. Certain information contained herein has been derived from sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, we makes no representation or warrant with respect to the accuracy of such information. Trademarks and trade names referred to in this presentation are the property of their respective owners. We do not ...

Third Quarter 2025 Earnings November 10, 2025 " Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include ...

Third Quarter 2025 Investor Presentation Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of iHeartMedia, Inc. and its subsidiaries (the "Company"), to be materially different from any future results, performance or achievements expressed or im ...

Financial Performance - Q3 2025 revenue reached $33.3 million, a significant increase of approximately 27 times year-over-year[10, 12, 13] - Gross margin for Q3 2025 was 270%, compared to 403% in Q3 2024[10, 12, 13] - Adjusted EBITDA improved by 59% year-over-year, resulting in a loss of $60 million in Q3 2025 compared to a loss of $147 million in Q3 2024[10, 12, 13] - Total cash and cash equivalents increased by approximately 7% quarter-over-quarter to $619 million as of September 30, 2025[10, 12, 13] Commercial Pipeline and Backlog - The company's backlog as of September 30th reached $920 million, an increase of 112% year-to-date[10, 15] - The developed pipeline is valued at $21 billion[15] - Executed projects have generated $583 million in revenue since the company's IPO[15] Guidance and Strategy - The company reiterated its 2025 revenue guidance of $200 million to $250 million[17, 18] - The company anticipates a gross margin of 14-16% for the full year 2025[17, 18] - The company projects an ending cash balance of $75 million to $100 million for the full year 2025[17, 18]